

Cell-Specific Adenovirus

Fig. 1A





Fig. 1B



Taxol (0.625 nM) + CV787 (MOI=0.01)





Fig. 2



5/42

CV787 (moi=0.01) + Taxotere (3.12nM)




Fig. 4

6/42

Mitoxantrone (100 nM) + CV787 (moi=0.1)





Fig. 5

Etoposide (500 ng/ml) + CV787 (moi=0.01)

7/42



Treatment Fig. 6

CV787 (moi=0.01) + Doxorubicin (50 ng/ml)




Fig. 7

9/42

Cisplatin (8.25 μ M) + CV787 (moi=0.1)




Fig. 8

5-Fluorouracil (35 μ M) + CV787 (moi=0.01)




Fig. 9

CV787 (moi=0.01) + ¹³⁷Cs (2 Gy)




Fig. 10

Days After Treatment

—●— Mock —●— CV787(0.01) —▲— ¹³⁷Cs (2 Gy) —■— CV787 + ¹³⁷Cs

12/42

Virus Yield (LNCaP)




Fig. 11

FIG. 11

13/42




Fig. 12

14/42

Taxol Does not Alter CV787's Specificity





Fig. 13

Days After Treatment



15/42

Specificity of CV787 + Mitoxantrone




FIG. 14

CV790 0.01moi/Doxorubicin 10ng/ml

16/42




Fig. 15

17/42

10ng/ml Doxorubicin first,
then 0.01 MOI CV790




Fig. 16

18/42

0.01 MOI CV790 and 10ng/ml Doxorubicin together




Fig. 17

19/42

CV790 0.1moi/Cisplatin 1ug/ml




Fig. 18

20/42

CV790 0.1moi/Taxol 0.5ng/ml




Fig. 19

CV790 0.1moi/5-FU 10ng/ml

21/42




Fig. 20

22/42

CV790 0.1moi/Mitoxantrone 4ng/ml




Fig. 21

CV790 0.1moi/Mitomycin C 10ng/ml

23/42




Fig. 22

Tumor Volume of LNCaP Xenograft Treated with CV787 and Taxol




Fig. 23

—◆— Control —△— CV787, 10⁷p/mm³ —●— Taxol, 15 mg/kg —■— CV787/Taxol

25/42




Fig. 24

Tumor Volume of LNCaP Xenograft Treated with CV787 and Taxol




Fig. 25

27/42

Tumor Volume of LNCaP Xenograft Treated with CV787 and Mitoxantrone




Fig. 26

28/42

Tumor Volume of LNCaP Xenografts Treated with CV787 and Estramustine




Fig. 27

LNCaP Xenograft Treated with CV787 and Docetaxel




Fig. 28

Weeks After Treatment

30/42

LNCaP Xenograft Treated with CV787 and Docetaxel




Fig. 29

31/42

Tumor Volume of Hep3B Treated with CV790 and Doxorubicin




Fig. 30

Tumor Volume of Hep3B Xenograft Treated with CV890 and Doxorubicin

32/42




Fig. 31

33/42




Fig. 32




Fig. 33

35/42




Fig. 34

36/42




Fig. 35

37/42




Fig. 36

38/42

FIG. 37

G ATG ACC GGC TCA ACC ATC GCG CCC ACA ACG GAC TAT CGC AAC ACC
46

Met Thr Gly Ser Thr Ile Ala Pro Thr Thr Asp Tyr Arg Asn Thr
1 5 10 15

ACT GCT ACC GGA CTA ACA TCT GCC CTA AAT TTA CCC CAA GTT CAT GCC
94

Thr Ala Thr Gly Leu Thr Ser Ala Leu Asn Leu Pro Gln Val His Ala
20 25 30

TTT GTC AAT GAC TGG GCG AGC TTG GAC ATG TGG TGG TTT TCC ATA GCG
142

Phe Val Asn Asp Trp Ala Ser Leu Asp Met Trp Trp Phe Ser Ile Ala
35 40 45

CTT ATG TTT GTT TGC CTT ATT ATT ATG TGG CTT ATT TGT TGC CTA AAG
190

Leu Met Phe Val Cys Leu Ile Ile Met Trp Leu Ile Cys Cys Leu Lys
50 55 60

CGC AGA CGC GCC AGA CCC CCC ATC TAT AGG CCT ATC ATT GTG CTC AAC
238

Arg Arg Arg Ala Arg Pro Pro Ile Tyr Arg Pro Ile Ile Val Leu Asn
65 70 75

CCA CAC AAT GAA AAA ATT CAT AGA TTG GAC GGT CTG AAA CCA TGT TCT
286

Pro His Asn Glu Lys Ile His Arg Leu Asp Gly Leu Lys Pro Cys Ser
80 85 90 95

CTT CTT TTA CAG TAT GAT TAA
307

Leu Leu Leu Gln Tyr Asp
100

09814357-101501

39/42




Fig. 38




Fig. 39

41/42




Fig. 40

Structure of CV876, CV882 and CV884

42/42




Fig. 41